IBI 3001
Alternative Names: IBI-3001Latest Information Update: 19 Jun 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodyabmics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Innovent Biologics plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/unresectable) in Australia (IV, Infusion), in May 2024 (NCT06349408)
- 12 Mar 2024 Preclinical trial in Solid tumours in China before March 2024 (Parenteral)